Skip to content
Home/Companies/Biotech/Recurv Pharma, Inc.

Recurv Pharma, Inc.

Biotech·United States·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Recurv Pharma, Inc.?

Recurv Pharma, Inc. is currently owned by TVM Capital Life Science through TVM Life Science Innovation (2016 vintage), since 2023.

Hand-verified · updated 2026-08-11

TVM Capital Life Science
Investor
TVM Capital Life Science
TVM Life Science Innovation · 2016 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive

More from TVM Life Science Innovation

Other portfolio companies in the same fund.

Anciata Therapeutics, Inc.
Active
BiotechUnited States· 2025
LAmAb Biologics, Inc.
Active
BiotechUnited States· 2023
Mage Biologics, Inc.
Active
BiotechUnited States· 2023
Auricula Biosciences
Active
BiotechUnited States· 2022
Immunorx Pharma, Inc.
Active
BiotechUnited States· 2021
Kent Imaging, Inc.
Kent Imaging, Inc.
Active
MedTechCanada· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Recurv Pharma, Inc.

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Recurv Pharma, Inc..

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue